Navigation Links
Weil Gotshal Wins Major Victory for Applera; Secures Summary Judgment Invalidating Three Patents
Date:9/10/2007

NEW YORK, Sept. 10 /PRNewswire/ -- In a major victory for its client, Applera Corporation, a global leader in DNA sequencing technologies, Weil, Gotshal & Manges LLP won a summary judgment ruling invalidating three key contested life sciences patents. In the action, Enzo Biochem, Inc., had claimed that Applera's DNA sequencing reagents and instruments infringed the patents in question.

In a detailed 49-page Ruling, the Honorable Janet Bond Arterton of the United States District Court for the District of Connecticut concluded that the three patents were invalid for two separate reasons: first, that the patents were fatally indefinite because they fail to provide the public with adequate guidance of what is and what is not covered; and second that the patents were not novel because prior scientific publications described the same subject matter.

The case had been widely followed in the biotechnology industry because Applera's DNA sequencing reagents and instruments are core technologies enabling basic research into fundamental biological processes, as well as in applied fields such as diagnostic or forensic research.

The Weil Gotshal team was led by partners Nicholas Groombridge and Elizabeth Stotland Weiswasser. Mr. Groombridge, who late last year obtained the noteworthy trial judgment transferring inventorship and ownership of the U.S. patent that protected Imclone's blockbuster pharmaceutical, Erbitux(TM), argued the anticipation motion and commented, "We were gratified by the Court's ruling, which confirmed that these patents were not valid. When a company stands up to fight a patent, there is a clear benefit to the industry and consumers. The life sciences community, and the people and patients that it serves, owe a debt of gratitude to Applera for obtaining this win." Added Ms. Weiswasser, who argued the indefiniteness motion, "Judge Arterton's opinion carefully analyzes the patents and properly concludes that they are invalid."

About Weil, Gotshal & Manges

Weil, Gotshal & Manges LLP is an international law firm of 1,200 lawyers, including approximately 300 partners. Weil Gotshal is headquartered in New York, with offices in Austin, Boston, Budapest, Dallas, Frankfurt, Houston, London, Miami, Munich, Paris, Prague, Providence, Shanghai, Silicon Valley, Warsaw, Washington DC and Wilmington, and opening in Hong Kong in October 2007. Weil Gotshal's Intellectual Property Litigation practice was honored as the leading practice of its kind by Chambers USA with its 2007 Award of Excellence.

For more, contact: Mike Ford, Media Relations Manager

(212) 833-3999

mike.ford@weil.com

Rubenstein Associates, Rhonda Walker

212-843-8338

rwalker@rubenstein.com


'/>"/>
SOURCE Weil, Gotshal & Manges LLP
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. Determination of Acepromazine and its Major Metabolite in Equine Serum by LC-MS/MS using the Finnigan LCQ Deca XP Plus Ion Trap Mass Spectrometer
2. Wisconsin building toward the major leagues of venture capital
3. Six things to consider before a major software implementation
4. New company eyes major ethanol production facility
5. Boston equity firm becomes majority owner of Cedarburg-based Mortgagebot
6. University of Michigan plans major stem cell research center
7. BellBrook Labs gets major research funding
8. API announces major healthcare contracts
9. Top 20 big pharmas represent majority of world pharma market
10. Researchers report major advance in gene therapy technique
11. TrafficCast secures $2M from Phenomenelle Angels, NEW Capital Fund
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/29/2016)... Diego, CA (PRWEB) , ... April 29, 2016 , ... ... Foundation (NSCF) to support the development of a patient-specific stem cell therapy for the ... in the lab of Dr. Jeanne Loring at The Scripps Research Institute in San ...
(Date:4/28/2016)... ... April 28, 2016 , ... Connecticut Innovations ... growing companies, today announced the launch of VentureClash , a $5 million ... , “VentureClash looks to attract the best early-stage companies here in Connecticut, ...
(Date:4/27/2016)... ... ... Shimadzu Scientific Instruments (SSI) will be showcasing a broad ... Expo. Shimadzu’s high-performance instruments enable laboratories to test cannabis products for potency, moisture, ... booth 1021 to learn how Shimadzu’s instruments can help improve QA/QC testing, peak ...
(Date:4/27/2016)... ... April 27, 2016 , ... The ... announce the appointment of John Tilton as Chief Commercial Officer.  Mr. Tilton joined ... of the founding commercial leaders responsible for the commercialization of multiple orphan drug ...
Breaking Biology Technology:
(Date:4/26/2016)... BANGALORE, India and LONDON ... Infosys Finacle, part of EdgeVerve Systems, a ... ), and Onegini today announced a partnership to ... banking solutions.      (Logo: http://photos.prnewswire.com/prnh/20151104/283829LOGO ... banks to provide their customers enhanced security to ...
(Date:4/15/2016)... -- A new partnership announced today will help life ... a fraction of the time it takes today, ... insurance policies to consumers without requiring inconvenient and ... rapid testing (A1C, Cotinine and HIV) and higi,s ... pulse, BMI, and activity data) available at local ...
(Date:4/13/2016)... -- IMPOWER physicians supporting Medicaid patients in Central ... in telehealth thanks to a new partnership with higi. ... patients can routinely track key health measurements, such as ... when they opt in, share them with IMPOWER clinicians ... retail location at no cost. By leveraging this data, ...
Breaking Biology News(10 mins):